Delivery Order SPE2DB20D3103-SPE2DB21FP9V8
- Not listed
- This federal contract award, valued at $48,051.00, was issued by the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of TWINRIX VACCINE SYRINGEML, a hepatitis A and hepatitis B vaccine. The award is a delivery order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued up to $999,999,999.00 and running through November 2026. This IDC serves...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $1,293.61 firm fixed-price delivery order is for the supply of TWINRIX VACCINE SYRINGEML, a hepatitis A and hepatitis B vaccine. This award is part of Amerisourcebergen's larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which covers a comprehensive range of pharmaceutical products and medical supplies to support...
- This federal contract award is a delivery order, valued at $54,432.96, issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of TWINRIX VACCINE SYRINGEML, a hepatitis A and hepatitis B vaccine, with an ultimate completion date of November 23, 2021. The contract is a firm fixed-price Indefinite Delivery Contract (IDC) with a ceiling value of $999,999,999.00, which serves as the primary vehicle for...
- This federal contract award, valued at $182,299.40, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of Twinrix vaccine syringes, a hepatitis A and hepatitis B combination vaccine, to support military and federal healthcare programs. The contract is a Firm Fixed Price Delivery Order with an ultimate completion date of September 6, 2022. Amerisourcebergen, a major pharmaceutical distributor, holds a...
- This federal contract award, valued at $1,400.31, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of TWINRIX VACCINE SYRINGEML, a hepatitis A and hepatitis B vaccine, to support military treatment facilities and other government healthcare programs. The award is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical, valued at up...
- This federal contract award, valued at $3,472.45, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of TWINRIX VACCINE SYRINGEML, a hepatitis A and B vaccine, with a completion date of May 4, 2023. This award is not designated as a set-aside contract. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
- This federal contract award, valued at $3,933.56, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of TWINRIX VACCINE SYRINGEML, a combination hepatitis A and hepatitis B vaccine, to support various federal government healthcare programs. The award is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company,...
- This federal contract award, valued at $127,579.26, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of the TWINRIX VACCINE SYRINGE, a hepatitis A and hepatitis B combination vaccine, to support federal healthcare programs. The award is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order valued at $1,079.30 for the supply of the Twinrix vaccine. The contract was awarded by the Defense Logistics Agency (DLA), a defense agency, and has a completion date of November 15, 2022. The contract is a firm fixed-price delivery order and does not have a set-aside designation, indicating open competition. Amerisourcebergen is a major pharmaceutical distributor and healthcare...
- This federal contract award, valued at $14,793.66, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of TWINRIX vaccine syringes and has a completion date of May 19, 2023. The contract is a Firm-Fixed-Price Delivery Order with no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc.,...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB21FP9V8Delivery Order
This federal contract award, valued at $81,649.44, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the Cencora, Inc. pharmaceutical distribution company. The contract is for the delivery of TWINRIX vaccine syringes, a hepatitis A and B combination vaccine, to support military healthcare programs. The award is a delivery order placed against Amerisourcebergen's Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. This IDC serves as the primary vehicle for the company to provide a comprehensive range of pharmaceutical products and medical supplies to DLA facilities worldwide, including specialty medications, generic drugs, medical devices, and vaccines. The contract does not have a set-aside designation, indicating open competition. In addition to the DLA contract, Amerisourcebergen also holds a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $81.6k | 8/23/21 |